- Home
- IDYA vs SWTX Comparison
IDYA vs SWTX Comparison
Compare IDYA & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- SWTX
- Stock Information
- Founded
- IDYA 2015
- SWTX 2017
- Country
- IDYA United States
- SWTX United States
- Employees
- IDYA N/A
- SWTX N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- IDYA Health Care
- SWTX Health Care
- Exchange
- IDYA Nasdaq
- SWTX Nasdaq
- Market Cap
- IDYA 2.6B
- SWTX 2.2B
- IPO Year
- IDYA 2019
- SWTX 2019
- Fundamental
- Price
- IDYA $26.91
- SWTX $37.38
- Analyst Decision
- IDYA Strong Buy
- SWTX Strong Buy
- Analyst Count
- IDYA 12
- SWTX 5
- Target Price
- IDYA $53.67
- SWTX $67.00
- AVG Volume (30 Days)
- IDYA 997.6K
- SWTX 1.1M
- Earning Date
- IDYA 11-04-2024
- SWTX 11-12-2024
- Dividend Yield
- IDYA N/A
- SWTX N/A
- EPS Growth
- IDYA N/A
- SWTX N/A
- EPS
- IDYA N/A
- SWTX N/A
- Revenue
- IDYA $3,922,000.00
- SWTX $135,487,000.00
- Revenue This Year
- IDYA N/A
- SWTX $3,426.90
- Revenue Next Year
- IDYA $251.89
- SWTX $88.92
- P/E Ratio
- IDYA N/A
- SWTX N/A
- Revenue Growth
- IDYA N/A
- SWTX N/A
- 52 Week Low
- IDYA $24.72
- SWTX $28.21
- 52 Week High
- IDYA $47.74
- SWTX $53.92
- Technical
- Relative Strength Index (RSI)
- IDYA 45.25
- SWTX 46.01
- Support Level
- IDYA $24.72
- SWTX $37.26
- Resistance Level
- IDYA $26.86
- SWTX $42.51
- Average True Range (ATR)
- IDYA 1.23
- SWTX 1.60
- MACD
- IDYA 0.04
- SWTX -0.75
- Stochastic Oscillator
- IDYA 46.89
- SWTX 4.37
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.